696 records found.
Sep 20, 2019
Innovent Provides Update on Two Studies of IBI301 (Rituximab Biosimilar) in the Treatment of CD20-positive Lymphoma at Annual Meeting of CSCO
Sep 20, 2019
CHMP Issues Positive Opinion to Expand Trulicity® (dulaglutide) Label to Include Results from REWIND Cardiovascular Outcomes Trial
Sep 19, 2019
Lilly Announces Webcast to Discuss ESMO 2019 Presentations
Sep 19, 2019
Chipscreen Biosciences's Oringinal New Drug Bilessglu® (for Type 2 Diabetes): Commercialization Application Accepted
Sep 17, 2019
Oramed Announces Last Patient Treated in Pivotal Phase IIb Trial of Oral Insulin ORMD-0801
Sep 16, 2019
Abbott and Sanofi Partner to Integrate Glucose Sensing and Insulin Delivery Technologies to Help Change the Way Diabetes is Managed
Sep 11, 2019
ANI Pharmaceuticals Announces Launch of Vancomycin Hydrochloride for Oral Solution USP, 250mg/5mL
Sep 11, 2019
Dance Biopharm Partners With DarioHealth to Expand Access to Digital Therapeutics Platform for Patients With Chronic Diseases
Sep 10, 2019
Dermatropin HGH Now Available Without a Prescription Directly to Consumers
Sep 09, 2019
Thermo Fisher Scientific Signs Agreement with Lilly Oncology for Companion Diagnostic to be Used with RET Inhibitor
Sep 09, 2019
Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer
Sep 09, 2019
Feasibility Study Supports the use of Intralymphatic Injections of Diamyd®
Sep 06, 2019
Global Drugs for Erectile Dysfunction Market Will Grow to $5.18 Billion By 2022 a Report by The Business Research Company
Sep 05, 2019
Lilly's Pain Clinical Trial Protocol Selected for FDA Complex Innovative Trial Designs Pilot Meeting Program
Sep 04, 2019
Lilly to Participate in Morgan Stanley Global Healthcare Conference
Aug 28, 2019
Innovent Reports Interim Results for Fiscal Year 2019
Aug 28, 2019
Glucose Health, Inc. 2019 SIX MONTH FISCAL UPDATE - Revenue Up; Gross Profit Up; Liabilities Down
Aug 26, 2019
Lilly Receives U.S. FDA Approval for Taltz® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
Aug 23, 2019
Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib, in Combination with Topical Corticosteroids in Adult Patients with Moderate to Severe Atopic Dermatitis
Aug 22, 2019
Human Growth Hormone Market to be Worth US$ 5,261.5 Million by 2026, Growing Cases of Chronic Diseases to Accelerate the Growth - TMR

Pages